Mylan announces no need for recall due to matrix design of Fentanyl patch
PITTSBURG As a result of the recall initiated by Ortho-McNeil-Janssen Pharmaceuticals for 25 mcg/hr Duragesic sold by Pricara, Mylan has announced that its product, the Fentanyl Transdermal System, will not take part.
According to published reports, all 25 mcg/hr Fentanyl patches are being voluntarily recalled by pharmacies and wholesalers, because during manufacturing there may have been a cut along one side of the drug reservoir within the patch. Mylan’s FTS patch does not fit this category, however, because it is made up of a matrix patch—rather than a reservoir patch—which does not leak.
“We have always believed that our Fentanyl Transdermal System is differentiated from all other Fentanyl patches in the U.S. market because of its unique matrix design,” said Mylan vice chairman and chief executive officer Robert Coury, “This is an important product characteristic that should be recognized and understood when choosing a Fentanyl Transdermal System.”
IVoice announces patent on new product for easy medicine consumption
MATAWAN, N.J. iVoice has created a new product that will organize the way that patients consume pills. According to published reports, the invention is a medicine container that has speaking instructions.
iVoice has filed a patent application with the U.S. Patent and Trademark Office under the title, “Methodology for Wirelessly Loading Speaking Medicine Containers, with an internal clock.”
The new iVoice product contains an internal clock, which starts when a patient activates the audio playback that, with recurring use, creates a message that displays how many pills the patient should have left, and if that “predetermined amount” is not in the container, a warning is displayed for the patient to contact a doctor or pharmacist. Other features include a medicine container starting table count, required consumption data and self-programming.
FTC files complaint over Cephalon’s attempt at protection of Provigil market
WASHINGTON Cephalon is facing a lawsuit filed by antitrust enforcers regarding its Narcolepsy medicine, Provigil.
Provigil is Cephalon’s best-selling drug, and according to the Wall Street Journal, the civil complaint filed by the Federal Trade Commission stated that Cephalon was illegally delaying the sale of the drug by four rivals that were slated to produce and market the generic version of the drug. The sales of Provigil are a recorded $800 million per year.
According to the Wall Street Journal report, companies including Teva Pharmaceuticals, Ranbaxy Pharmaceuticals, Barr Pharmaceuticals, and Mylan Pharmaceuticals, were given a combined $200 million to push off the genetic version of their drug from market entry until 2012.
Cephalon denies any wrongdoing. “The transactions we reached met the letter and spirit of the law in every way,” Frank Baldino, Cephalon’s chief executive, said, “and we will litigate this matter, and we will prevail.”